Dbv Technologies
- Address
- 107 Avenue De La Republique
Sponsor Overview
Specializations
Food Allergy
Dbv Technologies focuses on peanut allergy, with clinical research centered on improving desensitization and long-term management in children affected by this IgE-mediated allergy.
- Peanut allergy
- Food allergen immunotherapy
- Allergic disease in children
The sponsor’s research activity includes studies in young pediatric populations, reflecting a strong interest in early-life allergy care and the clinical handling of persistent food hypersensitivity.
Epicutaneous Immunotherapy
Its clinical program is built around epicutaneous immunotherapy for peanut allergy, using skin-based exposure approaches aimed at reducing allergic reactivity and supporting sustained treatment benefit.
- Epicutaneous delivery
- Viaskin Peanut
- Immune tolerance induction
Research in this area addresses both efficacy and safety in children across multiple age groups, including toddlers and school-age patients.
Pediatric Allergy
Dbv Technologies places clear emphasis on pediatric allergy, particularly in children with confirmed peanut hypersensitivity who require age-appropriate therapeutic options.
- Children aged 1 to 3 years
- Children aged 4 to 7 years
- Long-term allergy management
The sponsor’s studies span early childhood through later childhood, highlighting interest in treatment strategies suited to developmental stages and family-centered allergy care.
Allergy Safety and Tolerability
A major therapeutic theme in the sponsor’s portfolio is the safety and tolerability of allergy treatment, with attention to how children respond to prolonged therapy for food allergy.
- Treatment safety
- Long-term tolerability
- Pediatric risk management
This area includes monitoring of clinical outcomes over extended periods in children receiving treatment for peanut allergy.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 μg in 4-7-year-old Children with Peanut Allergy (VITESSE) |  France Germany Ireland Spain The Netherlands | Not Recruiting |
| A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy with DBV712 250 µg in 1-through 3-year-old Children with Peanut Allergy | France Ireland Spain The Netherlands | Not Recruiting |
| Long-term Evaluation of DBV712 in Pediatric Peanut Allergy: An Open-label Extension Study on Clinical Benefit and Safety | Germany The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 6 molecules, of which 3 are not being studied by other sponsors.
This sponsor has worked with 21 sites across their trial portfolio.
Therapeutic Focus
- 1.Immune System Diseases3 trials322 other sponsors
Partnered Research Centres
21 centres- Address
- 165 Chemin Du Grand Revoyet, 69310 Pierre Benite
- Address
- 4 Rue Larrey, 49100 Angers
- Address
- Boulevard Tanguy Prigent, 29200 Brest
- Address
- Rue Michel Polonovski, 59037 Lille
- Address
- 80 Avenue Augustin Fliche, 34295 Montpellier
- Address
- Mill Road, Blanchardstown, D15 RRN1 Dublin
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Dbv Technologies.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.